D&O Insurance for SPAC Transactions — Three Phases, Three Different Programs

D&O insurance for SPAC transactions does not follow the same structure as traditional IPO D&O. There are three distinct phases — the SPAC IPO, the business combination (de-SPAC), and the newly public operating company — each with different insured parties, different risk profiles, and different D&O policy structures required. The authoritative annual reference is Woodruff Sawyer's Guide to D&O Insurance for SPAC IPOs, now published under the Gallagher brand.

Phase 1 — The SPAC IPO

When a SPAC completes its own IPO to raise funds for the trust account, it needs D&O insurance immediately. This Phase 1 policy covers the SPAC's directors and officers — typically the sponsor team — against claims arising from the SPAC's own public company status before a merger target is identified.

Key characteristics of Phase 1 SPAC D&O:

• Covers the SPAC entity and its directors/officers from the day the SPAC IPO is declared effective
• The trust account structure and the nature of the SPAC business model are unusual risk factors that specialist carriers understand but generalist carriers often do not price correctly
• Warrant accounting treatment (following the 2021 SEC guidance) is a known source of claims and carriers have priced this in
• Premiums are typically modest relative to operating company D&O because the SPAC has no operations — but the litigation risk from inadequate disclosure or sponsor conflicts is real

Phase 2 — The Business Combination

When the SPAC identifies and announces a merger target, the D&O risk landscape changes substantially. The S-4 registration statement, the proxy solicitation, the fairness opinion, and the PIPE offering all create new liability exposure for both the SPAC's directors and the target company's directors and officers.

Phase 2 coverage requirements include:

• Run-off (tail) coverage for the SPAC: When the SPAC merges into the combined company, the SPAC entity ceases to exist. A "tail" policy extends coverage for claims that arise after the merger for acts that occurred during the SPAC's operational period.
• Target company D&O: The target's own directors and officers need coverage for their participation in the S-4 process, the merger negotiations, and any claims arising from the business combination disclosures.
• Representations and warranties insurance (RWI): Increasingly common in SPAC transactions to backstop the representations made in the merger agreement.
• The gap period: The window between the SPAC IPO policy renewal date and the de-SPAC close can create coverage gaps if not actively managed. This is one of the most common D&O mistakes in SPAC transactions.

Phase 3 — The Newly Public Operating Company

Once the de-SPAC transaction closes, the combined entity is a newly public operating company with D&O insurance needs essentially identical to a company that went public through a traditional IPO — but with additional complications:

• The financial projections included in the S-4 create ongoing litigation exposure if the company underperforms — plaintiff attorneys cite S-4 projections in class action complaints for years after closing
• The post-SPAC company often has a more complex governance structure (earnout shares, warrants, PIPE investor rights) that affects D&O underwriting
• Many de-SPAC companies have weaker public company infrastructure than traditional IPO companies, which carriers factor into pricing

Run-Off Insurance and the Obligation to the SPAC

When a SPAC completes its business combination and merges with a target, the SPAC entity effectively ceases to exist. The SPAC's own directors and officers — the sponsor team — retain personal liability for any claims arising from the SPAC's pre-merger activities even after the merger closes. Run-off (tail) insurance covers this residual exposure:

• What it covers: Claims arising from the SPAC's IPO prospectus, the proxy statement for the shareholder vote, the fairness of the merger terms, and any alleged misrepresentations made by the SPAC before or during the deal process
• Who pays for it: The SPAC's D&O policy typically includes a run-off provision; alternatively, run-off coverage is purchased as a separate policy at or before the merger closing
• Duration: Standard run-off periods are 6 years (matching the statute of limitations for securities fraud claims)
• Cost: SPAC run-off coverage typically costs 150–300% of the annual premium — a one-time payment for 6 years of tail coverage

2025–2026 SPAC D&O Premium Benchmarks

The SPAC D&O market has improved substantially from the peak of 2021–2022, when surging SPAC-related securities class action filings drove premiums to historic highs. Current market conditions:

• Phase 1 (SPAC IPO) premiums: $500K–$2M/year for a $300M SPAC with a $10M–$20M primary layer — significantly below the 2021 peak of $2M–$5M for similar coverage
• Phase 2 (de-SPAC/business combination) incremental: Negotiated at the time of the specific de-SPAC transaction; target company risk profile is the primary pricing driver
• Key pricing drivers: Target company sector (biotech and fintech are higher), complexity of the deal structure, quality of the SPAC sponsor's track record, and whether the target company has any pre-existing litigation or regulatory exposure

Woodruff Sawyer (now under Gallagher) publishes an annual Guide to D&O Insurance for SPAC IPOs that is the primary market data reference for this specific coverage type. Engaging a specialist D&O broker with SPAC experience is essential — generalist brokers are not equipped to navigate Phase 1, Phase 2, and run-off coverage simultaneously.

The Authoritative Source

The Woodruff Sawyer annual guide (now published under the Gallagher brand) is the definitive reference on SPAC D&O insurance. Published each year with current market data, it covers all three phases, pricing benchmarks, coverage structures, and the litigation landscape. We reference it directly rather than summarize it — the data changes annually and the source is authoritative:

De-SPAC Litigation — A Distinct Risk Category

The wave of SPAC mergers from 2020–2022 generated a corresponding wave of securities litigation. The legal theories in de-SPAC litigation differ from traditional IPO class actions and are worth understanding specifically:

• Material misstatements in the proxy/prospectus: The S-4 or proxy statement filed in connection with the de-SPAC merger is treated like a registration statement — Section 11 and Section 14 of the Securities Exchange Act both provide plaintiff causes of action for material misstatements. Unlike a traditional IPO where statements are made by established public companies with audited histories, de-SPAC projections about the private target company's future performance often prove wildly optimistic.
• Forward-looking statements — the safe harbor problem: Traditional IPOs are not protected by the Private Securities Litigation Reform Act safe harbor for forward-looking statements in registration statements. De-SPAC mergers occupy an uncertain zone — some courts have found the PSLRA safe harbor applies to certain de-SPAC disclosures; others have not.
• Fiduciary duty claims: SPAC sponsors have significant conflicts of interest — they receive promote shares contingent on completing a deal, which creates pressure to close even unfavorable deals. Delaware courts have applied "entire fairness" review (the most stringent standard) to de-SPAC transactions, significantly increasing sponsor litigation exposure.
• Class certification: Securities class actions arising from de-SPAC mergers have had mixed results at the class certification stage — some courts have certified classes, others have not, depending on whether common questions predominate over individual questions about investor reliance.

PIPE Investor Claims

Most de-SPAC mergers include a PIPE (Private Investment in Public Equity) — a concurrent private placement to institutional investors who fund the acquisition consideration alongside the SPAC trust. PIPE investors have a distinct legal position and distinct claims exposure:

• PIPE investors purchase shares at the merger price pursuant to a private placement, not pursuant to the registered offering. Their claims against the company for misrepresentations are typically brought under Rule 10b-5 rather than Section 11.
• PIPE investors are often shown non-public projections about the target company during their PIPE due diligence process — projections that may later prove inaccurate. These investors may allege fraud in the inducement if projections were materially optimistic.
• D&O insurance for de-SPAC companies should explicitly address whether coverage extends to claims by PIPE investors — some policies exclude claims by "institutional investors" who conducted sophisticated diligence, while others cover them.

Sponsor Promote — Insurance Implications

The SPAC sponsor typically receives "promote shares" — founder shares representing 20% of the post-IPO SPAC share count, acquired for nominal consideration, that vest when the de-SPAC merger closes. The economic incentive created by the promote is at the center of most fiduciary duty litigation against sponsors:

• The sponsor's promote is worth zero if no deal is completed within the SPAC's life (typically 18–24 months). This creates a structural incentive to complete a deal — even one that may not be in the best interest of public SPAC shareholders.
• D&O coverage for the SPAC sponsor entity itself (as opposed to the individual directors and officers) requires specific coverage — the sponsor entity may not be covered under the individual-focused D&O policy without a specific insuring agreement.
• Some de-SPAC D&O programs now include "sponsor promote insurance" as a separate coverage layer that specifically addresses claims arising from the promote structure and conflicts of interest.
• Delaware's "entire fairness" standard for conflicted transactions means sponsors face a higher risk of personal liability in derivative suits — Side A DIC coverage for individual sponsors is particularly important in the de-SPAC context.